| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxamic Acids | 29 | 2014 | 454 | 2.860 |
Why?
|
| Leukemia, Myeloid, Acute | 34 | 2024 | 7259 | 2.710 |
Why?
|
| Histone Deacetylase Inhibitors | 25 | 2015 | 617 | 2.520 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2023 | 204 | 2.170 |
Why?
|
| Myeloproliferative Disorders | 7 | 2022 | 881 | 1.780 |
Why?
|
| HSP90 Heat-Shock Proteins | 19 | 2014 | 191 | 1.620 |
Why?
|
| Drug Synergism | 29 | 2022 | 1359 | 1.610 |
Why?
|
| Transcription Factors | 14 | 2024 | 5437 | 1.490 |
Why?
|
| Histone Deacetylases | 13 | 2016 | 364 | 1.440 |
Why?
|
| Antineoplastic Agents | 23 | 2023 | 14614 | 1.410 |
Why?
|
| Indoles | 21 | 2019 | 1028 | 1.360 |
Why?
|
| Nuclear Proteins | 15 | 2024 | 3438 | 1.310 |
Why?
|
| Histone Demethylases | 3 | 2023 | 144 | 1.300 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2024 | 2616 | 1.300 |
Why?
|
| Enzyme Inhibitors | 15 | 2017 | 1944 | 1.270 |
Why?
|
| Sulfonamides | 10 | 2022 | 1933 | 1.190 |
Why?
|
| Cell Cycle Proteins | 12 | 2023 | 2115 | 0.950 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2023 | 460 | 0.920 |
Why?
|
| Cell Line, Tumor | 35 | 2024 | 14825 | 0.810 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2022 | 4960 | 0.790 |
Why?
|
| Apoptosis | 30 | 2021 | 7752 | 0.790 |
Why?
|
| Proteins | 3 | 2021 | 2043 | 0.780 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2022 | 66 | 0.770 |
Why?
|
| DNA Helicases | 1 | 2024 | 450 | 0.770 |
Why?
|
| DNA-Binding Proteins | 9 | 2021 | 5001 | 0.760 |
Why?
|
| Xenograft Model Antitumor Assays | 17 | 2024 | 3911 | 0.760 |
Why?
|
| Epigenesis, Genetic | 7 | 2023 | 1442 | 0.730 |
Why?
|
| Tumor Cells, Cultured | 14 | 2022 | 5759 | 0.690 |
Why?
|
| Proteolysis | 2 | 2021 | 377 | 0.680 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 11 | 2024 | 1542 | 0.660 |
Why?
|
| Adenosine | 2 | 2012 | 296 | 0.640 |
Why?
|
| Janus Kinase 2 | 5 | 2016 | 754 | 0.640 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2023 | 1737 | 0.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 18 | 2023 | 16640 | 0.630 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2019 | 288 | 0.580 |
Why?
|
| Azepines | 2 | 2015 | 134 | 0.560 |
Why?
|
| Neoplastic Stem Cells | 3 | 2024 | 1457 | 0.560 |
Why?
|
| Sirtuin 2 | 1 | 2016 | 18 | 0.550 |
Why?
|
| Peroxiredoxins | 1 | 2016 | 18 | 0.550 |
Why?
|
| Pyrimidines | 9 | 2018 | 3662 | 0.540 |
Why?
|
| Mice | 31 | 2024 | 35574 | 0.530 |
Why?
|
| Histone Acetyltransferases | 2 | 2017 | 433 | 0.520 |
Why?
|
| Ubiquitins | 1 | 2016 | 95 | 0.520 |
Why?
|
| beta Catenin | 3 | 2020 | 682 | 0.520 |
Why?
|
| Animals | 38 | 2024 | 62012 | 0.500 |
Why?
|
| Fusion Proteins, bcr-abl | 6 | 2008 | 1143 | 0.480 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2020 | 5403 | 0.460 |
Why?
|
| Auranofin | 1 | 2014 | 36 | 0.460 |
Why?
|
| Mice, Inbred NOD | 8 | 2018 | 897 | 0.440 |
Why?
|
| Triazoles | 2 | 2015 | 627 | 0.440 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2015 | 749 | 0.430 |
Why?
|
| Acetylation | 14 | 2017 | 514 | 0.420 |
Why?
|
| Piperazines | 6 | 2012 | 2145 | 0.420 |
Why?
|
| Polycomb Repressive Complex 2 | 5 | 2012 | 161 | 0.410 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 202 | 0.410 |
Why?
|
| Humans | 80 | 2024 | 270462 | 0.410 |
Why?
|
| Leukemia | 5 | 2024 | 1719 | 0.410 |
Why?
|
| Hydrazines | 1 | 2014 | 213 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 2453 | 0.400 |
Why?
|
| HL-60 Cells | 9 | 2011 | 318 | 0.390 |
Why?
|
| Resorcinols | 1 | 2011 | 27 | 0.390 |
Why?
|
| Histones | 8 | 2017 | 1512 | 0.390 |
Why?
|
| Signal Transduction | 15 | 2020 | 12098 | 0.380 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 3 | 2024 | 214 | 0.380 |
Why?
|
| Oxidative Stress | 2 | 2016 | 1149 | 0.380 |
Why?
|
| Janus Kinases | 1 | 2012 | 175 | 0.380 |
Why?
|
| Isoxazoles | 1 | 2011 | 81 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 9036 | 0.370 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2022 | 1013 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2013 | 2073 | 0.350 |
Why?
|
| K562 Cells | 8 | 2009 | 345 | 0.350 |
Why?
|
| Protein Binding | 8 | 2019 | 3485 | 0.340 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2013 | 1564 | 0.340 |
Why?
|
| Repressor Proteins | 4 | 2014 | 1717 | 0.340 |
Why?
|
| Cell Proliferation | 10 | 2021 | 7234 | 0.330 |
Why?
|
| Mice, SCID | 7 | 2018 | 1825 | 0.330 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 5 | 2012 | 263 | 0.320 |
Why?
|
| Lactams, Macrocyclic | 8 | 2010 | 90 | 0.320 |
Why?
|
| Benzoquinones | 8 | 2010 | 110 | 0.320 |
Why?
|
| HSP70 Heat-Shock Proteins | 5 | 2013 | 163 | 0.310 |
Why?
|
| Pyrazoles | 3 | 2018 | 1539 | 0.310 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 1327 | 0.310 |
Why?
|
| Imidazoles | 4 | 2016 | 1057 | 0.300 |
Why?
|
| Immunoprecipitation | 5 | 2016 | 589 | 0.290 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2008 | 2633 | 0.290 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 1436 | 0.290 |
Why?
|
| Histone Deacetylase 6 | 7 | 2014 | 45 | 0.290 |
Why?
|
| Breast Neoplasms | 9 | 2016 | 16182 | 0.290 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 2475 | 0.280 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2009 | 314 | 0.280 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2022 | 581 | 0.270 |
Why?
|
| Thiazoles | 2 | 2008 | 723 | 0.260 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 10699 | 0.250 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 3341 | 0.250 |
Why?
|
| Leukemia, Myeloid | 4 | 2021 | 993 | 0.240 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 1876 | 0.240 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 2 | 2023 | 53 | 0.240 |
Why?
|
| Gene Knockdown Techniques | 5 | 2019 | 1077 | 0.240 |
Why?
|
| Cell Cycle | 6 | 2014 | 2137 | 0.230 |
Why?
|
| Bartonella bacilliformis | 1 | 2003 | 1 | 0.230 |
Why?
|
| Bartonella henselae | 1 | 2003 | 22 | 0.230 |
Why?
|
| Blood Platelet Disorders | 1 | 2024 | 35 | 0.220 |
Why?
|
| STAT5 Transcription Factor | 6 | 2016 | 226 | 0.220 |
Why?
|
| Cell Survival | 8 | 2019 | 3059 | 0.220 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 6 | 2023 | 838 | 0.220 |
Why?
|
| Mutation | 11 | 2023 | 15901 | 0.220 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 692 | 0.210 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2019 | 1366 | 0.210 |
Why?
|
| Genes, Bacterial | 1 | 2003 | 270 | 0.210 |
Why?
|
| Gene Silencing | 3 | 2021 | 827 | 0.200 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2022 | 71 | 0.200 |
Why?
|
| Receptors, Androgen | 3 | 2021 | 853 | 0.200 |
Why?
|
| Neoplasm Proteins | 7 | 2012 | 3344 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 3214 | 0.190 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2013 | 271 | 0.190 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 522 | 0.190 |
Why?
|
| Inhibitor of Apoptosis Proteins | 3 | 2012 | 202 | 0.190 |
Why?
|
| Rifabutin | 3 | 2005 | 26 | 0.190 |
Why?
|
| Escherichia coli Proteins | 1 | 2003 | 377 | 0.180 |
Why?
|
| Blotting, Western | 8 | 2019 | 3586 | 0.180 |
Why?
|
| RNA, Small Interfering | 6 | 2014 | 2196 | 0.180 |
Why?
|
| Aminopyridines | 1 | 2022 | 223 | 0.170 |
Why?
|
| Adenine | 2 | 2021 | 668 | 0.170 |
Why?
|
| Tubulin | 2 | 2011 | 202 | 0.170 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 7382 | 0.170 |
Why?
|
| GATA2 Transcription Factor | 2 | 2021 | 67 | 0.170 |
Why?
|
| Transcription Factor 4 | 1 | 2019 | 33 | 0.170 |
Why?
|
| Quinolines | 2 | 2013 | 400 | 0.170 |
Why?
|
| RNA Interference | 3 | 2012 | 1386 | 0.170 |
Why?
|
| Transcriptome | 2 | 2021 | 1954 | 0.160 |
Why?
|
| Immunoblotting | 3 | 2016 | 895 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2022 | 437 | 0.160 |
Why?
|
| Endoplasmic Reticulum | 2 | 2010 | 328 | 0.160 |
Why?
|
| Immunoglobulins | 1 | 2019 | 286 | 0.160 |
Why?
|
| Melanoma | 1 | 2016 | 5594 | 0.160 |
Why?
|
| Microscopy, Confocal | 3 | 2016 | 659 | 0.150 |
Why?
|
| Azacitidine | 4 | 2023 | 1218 | 0.150 |
Why?
|
| Chromatin | 3 | 2021 | 1042 | 0.150 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2023 | 3149 | 0.150 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 813 | 0.150 |
Why?
|
| Piperidines | 2 | 2021 | 1086 | 0.150 |
Why?
|
| Gene Expression | 4 | 2014 | 3641 | 0.140 |
Why?
|
| Staurosporine | 3 | 2013 | 147 | 0.140 |
Why?
|
| Bcl-2-Like Protein 11 | 2 | 2014 | 70 | 0.140 |
Why?
|
| Stress, Physiological | 2 | 2010 | 493 | 0.140 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 465 | 0.140 |
Why?
|
| Comet Assay | 1 | 2016 | 57 | 0.140 |
Why?
|
| Oxidants | 1 | 2016 | 50 | 0.140 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2014 | 622 | 0.140 |
Why?
|
| Pyridones | 1 | 2019 | 360 | 0.130 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2016 | 208 | 0.130 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2004 | 678 | 0.130 |
Why?
|
| Peroxidase | 1 | 2016 | 133 | 0.130 |
Why?
|
| Genes, myc | 2 | 2016 | 372 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 1081 | 0.130 |
Why?
|
| Nuclear Receptor Coactivator 3 | 2 | 2015 | 378 | 0.130 |
Why?
|
| RNA-Binding Proteins | 2 | 2023 | 1017 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2020 | 839 | 0.130 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 271 | 0.130 |
Why?
|
| bcl-X Protein | 3 | 2011 | 198 | 0.120 |
Why?
|
| Mice, Nude | 4 | 2019 | 4329 | 0.120 |
Why?
|
| Female | 19 | 2023 | 148723 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2014 | 562 | 0.120 |
Why?
|
| Oximes | 1 | 2016 | 191 | 0.120 |
Why?
|
| Binding Sites | 1 | 2019 | 2255 | 0.120 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 460 | 0.120 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2014 | 15 | 0.120 |
Why?
|
| Reactive Oxygen Species | 3 | 2014 | 1006 | 0.120 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2015 | 262 | 0.120 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2014 | 84 | 0.120 |
Why?
|
| Niacinamide | 1 | 2016 | 428 | 0.110 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2014 | 103 | 0.110 |
Why?
|
| U937 Cells | 3 | 2011 | 178 | 0.110 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2015 | 211 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2014 | 121 | 0.110 |
Why?
|
| Co-Repressor Proteins | 1 | 2014 | 120 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2016 | 383 | 0.110 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 172 | 0.110 |
Why?
|
| Class III Phosphatidylinositol 3-Kinases | 1 | 2013 | 12 | 0.110 |
Why?
|
| Imatinib Mesylate | 3 | 2006 | 1690 | 0.110 |
Why?
|
| Zebrafish | 1 | 2016 | 457 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2390 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2018 | 1712 | 0.110 |
Why?
|
| Phagosomes | 1 | 2013 | 72 | 0.110 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2012 | 45 | 0.100 |
Why?
|
| Molecular Chaperones | 2 | 2012 | 266 | 0.100 |
Why?
|
| Pyrrolidines | 1 | 2013 | 113 | 0.100 |
Why?
|
| Aurora Kinase B | 1 | 2012 | 67 | 0.100 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2012 | 78 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2009 | 634 | 0.100 |
Why?
|
| Nitriles | 2 | 2018 | 938 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 599 | 0.100 |
Why?
|
| Benzamides | 3 | 2006 | 1878 | 0.100 |
Why?
|
| Aurora Kinases | 1 | 2012 | 193 | 0.100 |
Why?
|
| Chloroquine | 1 | 2012 | 63 | 0.100 |
Why?
|
| Protein Kinases | 3 | 2014 | 902 | 0.100 |
Why?
|
| Cells, Cultured | 4 | 2014 | 5694 | 0.100 |
Why?
|
| RNA, Messenger | 5 | 2016 | 6397 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2015 | 1838 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 885 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2013 | 610 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2021 | 809 | 0.090 |
Why?
|
| Pyridazines | 1 | 2014 | 317 | 0.090 |
Why?
|
| Thrombocythemia, Essential | 1 | 2013 | 179 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1069 | 0.090 |
Why?
|
| BRCA1 Protein | 1 | 2014 | 525 | 0.090 |
Why?
|
| Aurora Kinase A | 1 | 2012 | 210 | 0.090 |
Why?
|
| Membrane Proteins | 3 | 2014 | 2929 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2013 | 385 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2015 | 2886 | 0.090 |
Why?
|
| Transcription Factor CHOP | 1 | 2010 | 24 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2011 | 4117 | 0.090 |
Why?
|
| Receptor, trkA | 1 | 2010 | 40 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 1126 | 0.090 |
Why?
|
| Isothiocyanates | 1 | 2010 | 44 | 0.090 |
Why?
|
| Polycythemia Vera | 1 | 2013 | 268 | 0.090 |
Why?
|
| Proteasome Endopeptidase Complex | 6 | 2011 | 592 | 0.090 |
Why?
|
| Autophagy | 2 | 2013 | 910 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2009 | 2099 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 639 | 0.080 |
Why?
|
| Milk Proteins | 3 | 2004 | 127 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2014 | 512 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2013 | 1709 | 0.080 |
Why?
|
| Gene Dosage | 1 | 2012 | 823 | 0.080 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2009 | 83 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 366 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 5141 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2009 | 669 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2012 | 552 | 0.080 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 276 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2010 | 354 | 0.080 |
Why?
|
| MCF-7 Cells | 3 | 2015 | 547 | 0.080 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2008 | 44 | 0.080 |
Why?
|
| Nitrophenols | 1 | 2008 | 95 | 0.080 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 796 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 330 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2008 | 530 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 10382 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 498 | 0.070 |
Why?
|
| Mastocytosis, Systemic | 1 | 2008 | 119 | 0.070 |
Why?
|
| S Phase | 1 | 2008 | 288 | 0.070 |
Why?
|
| Biphenyl Compounds | 1 | 2008 | 188 | 0.070 |
Why?
|
| Phosphorylation | 6 | 2012 | 4945 | 0.070 |
Why?
|
| Pyrazines | 1 | 2010 | 510 | 0.070 |
Why?
|
| Bacterial Proteins | 2 | 2003 | 1091 | 0.070 |
Why?
|
| Stem Cells | 1 | 2014 | 1217 | 0.070 |
Why?
|
| Receptors, Steroid | 1 | 2008 | 338 | 0.070 |
Why?
|
| Polycomb-Group Proteins | 1 | 2006 | 42 | 0.070 |
Why?
|
| DNA Damage | 2 | 2014 | 1981 | 0.070 |
Why?
|
| Protein Methyltransferases | 1 | 2006 | 46 | 0.070 |
Why?
|
| Cisplatin | 1 | 2014 | 2496 | 0.070 |
Why?
|
| Base Sequence | 4 | 2010 | 5437 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 381 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 1582 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2012 | 2033 | 0.070 |
Why?
|
| Dasatinib | 2 | 2008 | 881 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 4223 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2007 | 316 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 929 | 0.060 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2008 | 304 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 3528 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2003 | 1082 | 0.060 |
Why?
|
| Primary Myelofibrosis | 1 | 2013 | 913 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2010 | 4569 | 0.060 |
Why?
|
| Transcriptional Activation | 2 | 2021 | 1111 | 0.060 |
Why?
|
| Acute Disease | 2 | 2006 | 2494 | 0.060 |
Why?
|
| Rhizobiaceae | 1 | 2003 | 2 | 0.060 |
Why?
|
| Peptide Synthases | 1 | 2003 | 9 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2006 | 2091 | 0.060 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 1388 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2006 | 487 | 0.060 |
Why?
|
| Protein D-Aspartate-L-Isoaspartate Methyltransferase | 1 | 2003 | 4 | 0.060 |
Why?
|
| Bartonella | 1 | 2003 | 13 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2023 | 208 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2007 | 875 | 0.060 |
Why?
|
| Molecular Sequence Data | 3 | 2010 | 6686 | 0.050 |
Why?
|
| Neoplasms | 3 | 2017 | 15900 | 0.050 |
Why?
|
| Cell Division | 2 | 2005 | 2657 | 0.050 |
Why?
|
| Immune Evasion | 1 | 2023 | 76 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2005 | 766 | 0.050 |
Why?
|
| Species Specificity | 1 | 2003 | 794 | 0.050 |
Why?
|
| Genome, Bacterial | 1 | 2003 | 212 | 0.050 |
Why?
|
| Dilazep | 1 | 2021 | 4 | 0.050 |
Why?
|
| Checkpoint Kinase 1 | 2 | 2014 | 169 | 0.050 |
Why?
|
| Multigene Family | 1 | 2003 | 469 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 229 | 0.050 |
Why?
|
| Blast Crisis | 1 | 2004 | 587 | 0.050 |
Why?
|
| DNA Primers | 3 | 2010 | 1496 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2003 | 603 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2006 | 1825 | 0.050 |
Why?
|
| G1 Phase | 3 | 2009 | 305 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2003 | 372 | 0.050 |
Why?
|
| Recurrence | 2 | 2023 | 4873 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2023 | 409 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2014 | 437 | 0.050 |
Why?
|
| Cytarabine | 2 | 2023 | 2013 | 0.040 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2020 | 40 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2015 | 1462 | 0.040 |
Why?
|
| Male | 10 | 2023 | 128209 | 0.040 |
Why?
|
| Aged | 7 | 2023 | 73248 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2014 | 299 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2014 | 1685 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2024 | 677 | 0.040 |
Why?
|
| Acetanilides | 1 | 2018 | 17 | 0.040 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 115 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2014 | 537 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2354 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 960 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 87 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 700 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2023 | 1726 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 74 | 0.040 |
Why?
|
| Polyubiquitin | 2 | 2010 | 23 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 22466 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2021 | 521 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2014 | 33696 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 153 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 30976 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2013 | 3044 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 5856 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2011 | 1811 | 0.040 |
Why?
|
| G2 Phase | 2 | 2009 | 218 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2008 | 85 | 0.040 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 49 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 5070 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2023 | 1094 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 3603 | 0.030 |
Why?
|
| Middle Aged | 7 | 2023 | 90192 | 0.030 |
Why?
|
| Adenosine Triphosphate | 2 | 2008 | 586 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7909 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6253 | 0.030 |
Why?
|
| Paclitaxel | 2 | 2014 | 2100 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2005 | 2650 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 356 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 5251 | 0.030 |
Why?
|
| Adult | 5 | 2024 | 81851 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 184 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2014 | 65 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2015 | 135 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2005 | 374 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 4815 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2015 | 210 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2018 | 726 | 0.030 |
Why?
|
| Caspases | 1 | 2016 | 679 | 0.030 |
Why?
|
| Trans-Activators | 3 | 2004 | 1622 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 607 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 10258 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2004 | 274 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1101 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2013 | 88 | 0.030 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2013 | 38 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2004 | 295 | 0.030 |
Why?
|
| Ubiquitin | 2 | 2005 | 331 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2357 | 0.030 |
Why?
|
| Sumoylation | 1 | 2013 | 81 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 492 | 0.030 |
Why?
|
| Fatigue | 1 | 2018 | 1278 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 336 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 676 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 2834 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 5339 | 0.020 |
Why?
|
| Androgens | 1 | 2014 | 507 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 2031 | 0.020 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2011 | 88 | 0.020 |
Why?
|
| Phenotype | 1 | 2023 | 6503 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1347 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 624 | 0.020 |
Why?
|
| Indole Alkaloids | 1 | 2010 | 6 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 403 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2010 | 54 | 0.020 |
Why?
|
| Benzylamines | 1 | 2010 | 98 | 0.020 |
Why?
|
| Nerve Growth Factor | 1 | 2010 | 42 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 354 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2011 | 190 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 722 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 768 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2011 | 232 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 3478 | 0.020 |
Why?
|
| Mitochondria | 2 | 2008 | 1298 | 0.020 |
Why?
|
| Carbazoles | 1 | 2010 | 89 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 117 | 0.020 |
Why?
|
| Exons | 2 | 2004 | 1381 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2010 | 139 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2010 | 146 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1320 | 0.020 |
Why?
|
| Unfolded Protein Response | 1 | 2010 | 112 | 0.020 |
Why?
|
| Protein Folding | 1 | 2010 | 297 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 1609 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2010 | 305 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2010 | 166 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 12020 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 737 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2008 | 48 | 0.020 |
Why?
|
| Computational Biology | 1 | 2015 | 1293 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2010 | 628 | 0.020 |
Why?
|
| DNA Probes | 1 | 2008 | 247 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 704 | 0.020 |
Why?
|
| Bortezomib | 1 | 2010 | 543 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2015 | 1564 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2010 | 256 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 603 | 0.020 |
Why?
|
| Fungal Proteins | 1 | 2009 | 271 | 0.020 |
Why?
|
| Laminin | 1 | 2008 | 209 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 1121 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2008 | 318 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 958 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 206 | 0.020 |
Why?
|
| Proteomics | 1 | 2015 | 1426 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 637 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2008 | 111 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2010 | 579 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2008 | 581 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 686 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2013 | 1857 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2008 | 278 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 258 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 3399 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2008 | 246 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 631 | 0.020 |
Why?
|
| Antioxidants | 1 | 2010 | 522 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 3144 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2010 | 826 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 3242 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 968 | 0.020 |
Why?
|
| Lysine | 1 | 2008 | 426 | 0.020 |
Why?
|
| Pyrrolidinones | 1 | 2005 | 61 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 1280 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2005 | 123 | 0.020 |
Why?
|
| Collagen | 1 | 2008 | 726 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 2005 | 83 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 2421 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 5059 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2015 | 2762 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 2826 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2004 | 320 | 0.010 |
Why?
|
| Etoposide | 1 | 2005 | 905 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 5725 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 226 | 0.010 |
Why?
|
| DNA Repair | 1 | 2011 | 1910 | 0.010 |
Why?
|
| Child | 1 | 2024 | 30500 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 262 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2005 | 1255 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2005 | 743 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2003 | 276 | 0.010 |
Why?
|
| Remission Induction | 1 | 2008 | 3651 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2003 | 205 | 0.010 |
Why?
|
| Introns | 1 | 2003 | 461 | 0.010 |
Why?
|
| Taxoids | 1 | 2005 | 1015 | 0.010 |
Why?
|
| Point Mutation | 1 | 2004 | 788 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 3194 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 6524 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 1472 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 1431 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 9470 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 4044 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 1473 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 14003 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 1958 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 1899 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12509 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 3049 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 9039 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 4134 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 4479 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 12996 | 0.010 |
Why?
|